Climb Bio Inc (CLYM) Stock Analysis
Verdict: WATCH (do not buy)
Investment score: 42/100
Analysis as of
Is Climb Bio Inc stock worth reviewing? The TradeMates thesis
Overextended biotech at 52-week highs with looming dilution risk and recent heavy insider selling.
7-factor investment score
- Valuation: 50/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return/Beta: 35/100 (weight 15%)
Climb Bio Inc opportunities and risks
What speaks for CLYM
- Phase 2 Clinical Data Catalyst
What speaks against CLYM
- Imminent Dilutive Financing
Peers and competitors
Frequently asked questions about Climb Bio Inc (CLYM)
Is CLYM stock a good investment?
The TradeMates model rates Climb Bio Inc as WATCH (do not buy) with an investment score of 42/100. Overextended biotech at 52-week highs with looming dilution risk and recent heavy insider selling. This is algorithmic model output, not personal investment advice.
Is CLYM stock a buy?
The TradeMates model verdict for CLYM is WATCH (do not buy) with an investment score of 42/100. Treat this as a model signal to review, not a personal buy recommendation.